Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Arq. bras. cardiol ; 115(4): 717-718, out. 2020.
Article in Portuguese | SES-SP, LILACS, SES-SP | ID: biblio-1131352

ABSTRACT

Resumo Baixas doses de edoxabana e enoxaparina sódica foram objeto de uma comparação retrospectiva implementada com a técnica do escore de propensão a fim de mitigar os efeitos das diferenças nas características clínicas basais de duas coortes e minimizar o risco de viés. Posteriormente, usando um modelo de riscos proporcionais de Cox, avaliou-se a associação de cada tipo de terapia com o risco do composto de morte por todas as causas, acidente vascular cerebral/ataque isquêmico transitório, hospitalizações e ocorrência de sangramentos maiores. Para essa análise, um valor de p < 0,05 foi considerado estatisticamente significante. A terapia com enoxaparina e cirrose hepática como causadora de trombocitopenia estiveram associadas ao aumento do risco do endpoint composto (enoxaparina: hazard ratio (HR): 3,31; IC 95%: 1,54 a 7,13; p = 0,0023; cirrose hepática, HR: 1,04; 95% CI: 1,002 a 1,089; p = 0,0410). Por outro lado, a terapia com edoxabana mostrou-se significativamente associada à diminuição do risco do endpoint composto (HR: 0,071; 95% CI: 0,013 a 0,373; p = 0,0019). Com base nessa análise retrospectiva, o edoxaban em doses baixas seria uma ferramenta farmacológica segura e eficaz para a profilaxia de eventos cardioembólicos em pacientes com FA e trombocitopenia.


Abstract Low-dose edoxaban and enoxaparin sodium have been the subject of a retrospective comparison implemented with the propensity score technique in order to mitigate the effects of the differences in the basal clinical features of two cohorts and minimize the risk of bias. Subsequently, using a Cox proportional-hazards model, the association of each type of therapy with the risk of the composite of all-cause death, stroke/transient ischemic attack, hospitalizations and major bleeding events was assessed. For this analysis, a p-value < 0.05 was considered statistically significant. Therapy with enoxaparin and liver cirrhosis as causing thrombocytopenia were associated with increased risk of the composite endpoint (enoxaparin: hazard ratio (HR): 3.31; 95% CI: 1.54 to 7.13; p = 0.0023; liver cirrhosis, HR: 1.04; 95% CI: 1.002 to 1.089; p = 0.0410). Conversely, edoxaban therapy was significantly associated with decreased risk of the composite endpoint (HR: 0.071; 95% CI: 0.013 to 0.373; p = 0.0019). Based on this retrospective analysis, edoxaban at low doses would appear as an effective and safe pharmacological tool for the prophylaxis of cardioembolic events in patients with AF and thrombocytopenia.


Subject(s)
Humans , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Thrombocytopenia/chemically induced , Stroke/etiology , Stroke/prevention & control , Patients , Retrospective Studies , Treatment Outcome , Fibrinolytic Agents/adverse effects , Anticoagulants/adverse effects
4.
Rev. Soc. Bras. Med. Trop ; 51(6): 873-875, Nov.-Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-977108

ABSTRACT

Abstract Vancomycin is a first-line drug for treating methicillin-resistant Staphylococcus aureus. Thrombocytopenia is a rare adverse reaction to vancomycin treatment, and there are no reports of vancomycin-induced thrombocytopenia (VIT) in infants. We describe the case of a 3-month-old girl who was diagnosed with purulent meningitis. After 13 days of treatment with vancomycin, her platelet count reduced to 8 × 109/L. Vancomycin was discontinued, and intravenous methylprednisolone was administered. The platelet count returned to normal after 4 days. Patients, especially young children, receiving vancomycin for a long clinical course should undergo careful monitoring of laboratory indicators and blood tests.


Subject(s)
Humans , Female , Infant , Thrombocytopenia/chemically induced , Vancomycin/adverse effects , Thrombocytopenia , Thrombocytopenia/diagnosis , Severity of Illness Index , Vancomycin/therapeutic use , Meningitis, Bacterial/drug therapy
5.
Arch. endocrinol. metab. (Online) ; 62(6): 636-640, Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-983805

ABSTRACT

ABSTRACT Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital. Subjects and methods: Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3.8%) received treatment with MKIs. The median age at diagnosis of these patients was 53 years (range 20-70), and 75.9% of them were women. Sorafenib was prescribed as first-line treatment to 23 patients with differentiated thyroid cancer and as second-line treatment to one patient with advanced medullary thyroid cancer (MTC). Vandetanib was indicated as first-line treatment in 6 patients with MTC and lenvatinib as second-line treatment in two patients with progressive disease under sorafenib treatment. Results: During the follow-up of treatment (mean 13.7 ± 7 months, median 12 months, range 6-32), 5/29 (17.2%) patients presented rare adverse events. These rare adverse effects were: heart failure, thrombocytopenia, and squamous cell carcinoma during sorafenib therapy and squamous cell carcinoma and oophoritis with intestinal perforation during vandetanib treatment. Conclusions: About 3 to 5 years after the approval of MKI therapy, we learned that MKIs usually lead to adverse effects in the majority of patients. Although most of them are manageable, we still need to be aware of potentially serious and rare or unreported adverse effects that can be life-threatening.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Piperidines/adverse effects , Quinazolines/adverse effects , Carcinoma/drug therapy , Carcinoma, Medullary/drug therapy , Protein Kinase Inhibitors/adverse effects , Antineoplastic Agents/adverse effects , Oophoritis/chemically induced , Phenylurea Compounds/adverse effects , Quinolines/adverse effects , Thrombocytopenia/chemically induced , Time Factors , Thyroid Neoplasms/drug therapy , Retrospective Studies , Risk Factors , Follow-Up Studies , Kaplan-Meier Estimate , Sorafenib/adverse effects , Heart Failure/chemically induced , Intestinal Perforation/chemically induced
6.
Arch. argent. pediatr ; 115(6): 420-423, dic. 2017. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-887405

ABSTRACT

El linezolid es un antibiótico de la familia de las oxazolidinonas, que actúa inhibiendo la síntesis proteica. Se emplea en infecciones graves por cocos Gram-positivos multirresistentes. Sus principales efectos secundarios son los gastrointestinales y, con menor frecuencia, la neuropatía periférica, la acidosis láctica y la mielosupresión. Se presenta el caso clínico de un niño de 12 años con diagnóstico de osteoartritis séptica de cadera derecha con osteomielitis femoral en tratamiento con linezolid, que presentó un cuadro de intolerancia digestiva, asociado a astenia y pérdida de peso. Presentaba, además, anemia normocítica, junto con leucopenia y trombopenia leves, con datos sugestivos de alteración de la hematopoyesis en el frotis sanguíneo, sugerente de toxicidad por fármacos. El cuadro se resolvió con la interrupción de la administración del fármaco. La mielosupresión reversible asociada a linezolid se relaciona con tratamientos prolongados (> 28 días), por lo que son necesarios los controles hematológicos periódicos durante ellos.


Linezolid is an antibiotic of oxazolidinones family that inhibits proteical synthesis. It is used in several Gram-positive multirresistent infections. Its more frequent side effects are gastrointestinal, followed by peripheral neuropathy and myelosuppression. We report the case of a 12-year-old boy diagnosed with septic osteoarthritis of the hip and femoral osteomyelitis, following treatment with linezolid, who complained about digestive intolerance and weight loss. He showed severe normocytic anemia and mild leukopenia and thrombocytopenia with data of hematopoiesis disorder in the blood smear that suggested drug toxicity. These findings reverted when the treatment was discontinued. Reversible myelosuppression associated with linezolid is related to long treatments (more than 28 days). So it is necessary to check the blood count during long treatments.


Subject(s)
Humans , Male , Child , Osteomyelitis/drug therapy , Pseudomonas Infections/drug therapy , Thrombocytopenia/chemically induced , Osteoarthritis, Hip/drug therapy , Linezolid/adverse effects , Leukopenia/chemically induced , Anti-Bacterial Agents/adverse effects , Bone Marrow/drug effects , Femur
7.
Rev. méd. Chile ; 145(9): 1213-1217, set. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-902610

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.


Subject(s)
Humans , Female , Middle Aged , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Heparin/therapeutic use , Factor Xa Inhibitors/therapeutic use , Rivaroxaban/therapeutic use , Anticoagulants/adverse effects , Risk Factors , Treatment Outcome , Venous Thrombosis/etiology , Venous Thrombosis/prevention & control
8.
Rev. cuba. hematol. inmunol. hemoter ; 33(3): 42-54, jul.-set. 2017.
Article in Spanish | LILACS | ID: biblio-960420

ABSTRACT

La trombocitopenia puede tener varias causas, como la utilización de determinados fármacos. Los mecanismos causantes de la trombocitopenia inducida por fármacos incluyen disminución en la producción (supresión medular) o incremento en la destrucción (por mecanismos inmunes). Adicionalmente, la seudotrombocitopenia es un efecto in vitro, que se distingue de una real trombocitopenia inducida por medicamentos. Los estudios epidemiológicos son pocos, difieren en la metodología utilizada y describen una incidencia de 10 casos por millón de habitantes por año. El mecanismo fundamental de la trombocitopenia inducida por fármacos no está completamente esclarecido, pero al menos se plantean seis posibles mecanismos: anticuerpos inducidos por haptenos, anticuerpos dependientes del fármaco, inhibidores del complejo GP IIb-IIIa, autoanticuerpos inducidos por la droga, complejos inmunes y trombocitopenia inducida por heparina. La diana para los anticuerpos dependientes del fármaco son las glucoproteínas de la membrana plaquetaria, como las glucoproteínas Ib/IX y GPIIb/IIIa. El diagnóstico de trombocitopenia inducida por fármacos puede consistir en la identificación de síntomas clínicos (hematomas, petequias, sangramientos), la cuidadosa evaluación de la relación causal con el fármaco sospechoso, las investigaciones generales de laboratorio (conteos en sangre total, extendidos de sangre periférica, para descartar seudotrombocitopenia) y las pruebas serológicas para plaquetas. La trombocitopenia inducida por fármacos es una reacción adversa a medicamentos relativamente raros cuyas sus consecuencias pueden ser graves.


Thrombocytopenia can have several causes, including the use of certain drugs. The mechanism behind drug-induced thrombocytopenia is either a decrease in platelet production (bone marrow suppression) or an increased destruction (immune-mediated thrombocytopenia). In addition, pseudothrombocytopenia, an in vitro effect, has to be distinguished from true drug-induced thrombocytopenia. A small number of epidemiological studies, differing largely in the methodology used, describe incidences in the magnitude of 10 cases per 1 000 000 inhabitants per year. The underlying mechanism of drug-induced immune thrombocytopenia is not completely clarified, but at least six different types of antibodies appear to play a role; hapten-induced antibody, drug-dependent antibody ("compound" or "conformational-dependent" antibody), GPIIb-IIIa inhibitors, drug-induced autoantibody, immune complex and heparin-induced thrombocytopenia. Targets for drug-dependent antibodies are glycoproteins on the cell membrane of the platelets, such as glycoprotein (GP) Ib/IX and GPIIb/IIIa. Diagnosis of drug-induced immune thrombocytopenia may consist of identifying clinical symptoms (bruising, petechiae, bleeding), a careful evaluation of the causal relationship of the suspected causative drug, general laboratory investigation, such as total blood count and peripheral blood smear (to rule out pseudothrombocytopenia), and platelet serology tests. Although drug-induced thrombocytopenia is a relatively rare adverse drug reaction, its consequences may be severe.


Subject(s)
Humans , Male , Female , Thrombocytopenia/chemically induced , Thrombocytopenia/epidemiology , Blood Platelets , Diagnosis, Differential
9.
Rev. chil. obstet. ginecol. (En línea) ; 82(3): 304-306, jun. 2017.
Article in Spanish | LILACS | ID: biblio-899909

ABSTRACT

El tamoxifeno y el letrozol son fármacos muy utilizados en el tratamiento del cáncer de mama. Está descrito que la trombocitopenia (recuento plaquetario inferior a 100.000/mm3) es un efecto secundario raro tras el tratamiento con tamoxifeno. Sin embargo, no es un efecto adverso conocido del letrozol. Presentamos dos casos clínicos en los que tras tratamientos prolongados con estos fármacos nos encontramos con que las pacientes desarrollan trombocitopenia. En ambos casos, este efecto adverso desaparece en pocas semanas tras la retirada del fármaco.


Letrozole and tamoxifen are drugs used in the treatment of breast cancer. It is reported that thrombocytopenia (less than 100,000 / mm3 platelet count) is a rare side effect of tamoxifen. However, it is not a known side effect of letrozole. We present two cases in which after prolonged treatment with these drugs we found that the patients develop thrombocytopenia. In both cases, this adverse effect disappears a few weeks after drugs were stopped.


Subject(s)
Humans , Female , Middle Aged , Tamoxifen/adverse effects , Thrombocytopenia/chemically induced , Breast Neoplasms/drug therapy , Letrozole/adverse effects , Antineoplastic Agents/adverse effects
10.
Medicina (B.Aires) ; 76(4): 230-234, Aug. 2016. tab
Article in Spanish | LILACS | ID: biblio-841582

ABSTRACT

La trombocitopenia inducida por heparina (TIH) es una reacción adversa inmunológica mediada por la formación de anticuerpos contra el complejo heparina-factor plaquetario 4 (FP4), caracterizada por la presencia de trombocitopenia y la asociación paradojal de trombosis arterial o venosa. Es una complicación poco frecuente pero grave del uso de cualquier tipo de heparina. En tratados con procedimientos cardiovasculares como intervención coronaria percutánea y cirugía de revascularización cardiaca, la prevalencia de anticuerpos es significativamente mayor que en otros escenarios clínicos. El reconocimiento de las características clínicas y de laboratorio permite la suspensión inmediata de la heparina y la instauración de tratamiento anticoagulante alternativo, para evitar la progresión y formación de nuevos trombos y sus complicaciones. En la presente revisión se resumen las diferentes alternativas terapéuticas para la TIH, en particular los anticoagulantes orales directos (DOACS) como el dabigatran, rivaroxaban y apixaban que pueden proporcionar una nueva opción para el tratamiento de TIH.


Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse reaction due to antibodies to a multimolecular complex of heparin and platelet factor 4 (PF4) characterized by moderate thrombocytopenia and paradoxical arterial or venous thrombosis. It is a relatively infrequent complication related to the administration of any type of heparin. In patients undergoing percutaneous coronary revascularization or coronary artery by-pass graft the prevalence of HIT is higher than in other clinical settings. Recognizing clinical and laboratory features of HIT allow immediate discontinuation of heparin and the use of alternative anticoagulants to avoid serious thrombotic complications. In this review, we summarize different therapeutic options for the treatment of HIT with special emphasis on direct oral anticoagulants (DOACS) such as dabigatran, rivaroxaban and apixaban. DOACS might represent a therapeutic alternative for HIT treatment.


Subject(s)
Humans , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Heparin/adverse effects , Antithrombins/therapeutic use , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Thrombocytopenia/immunology , Thrombosis/prevention & control , Platelet Factor 4/immunology , Heparin/immunology , Venous Thrombosis/prevention & control , Anticoagulants/immunology
12.
Medicina (B.Aires) ; 75(5): 307-310, Oct. 2015. ilus
Article in Spanish | LILACS | ID: biblio-841518

ABSTRACT

La trombocitopenia inducida por heparina (TIH) es una reacción adversa inmunológica caracterizada por trombocitopenia y la asociación paradojal de trombosis arterial o venosa. Es causada por la formación de anticuerpos IgG contra el complejo multimolecular de heparina-factor plaquetario 4 (FP4). Fondaparinux es un inhibidor selectivo del factor Xa que tiene escasa afinidad por el FP4 y posee un menor potencial para inducir una respuesta inmunológica, haciendo del mismo un agente potencialmente útil en el tratamiento de la TIH. Se presenta el caso de una mujer de 73 años con TIH asociada a fenómenos trombóticos arteriales y venosos, que recibió exitosamente fondaparinux, con normalización del recuento plaquetario y sin progresión trombótica.


Heparin induced thrombocytopenia (HIT) is an immune-mediated adverse reaction characterized by thrombocytopenia and paradoxical arterial or venous thrombosis, due to the formation IgG antibodies directed to a multimolecular complex of heparin-platelet factor 4 (PF4). Fondaparinux is a selective factor Xa inhibitor with little affinity for PF4 and thus less likely to induce an immune response, making fondaparinux a potentially useful drug for the treatment of HIT. Herein we report the case of a 73 years old woman with HIT associated with arterial and venous thrombosis that was successfully treated with fondaparinux, with normalization of the platelet countand without progression of thrombosis.


Subject(s)
Humans , Female , Aged , Polysaccharides/therapeutic use , Thrombocytopenia/drug therapy , Heparin/adverse effects , Venous Thrombosis/drug therapy , Anticoagulants/therapeutic use , Platelet Count , Thrombocytopenia/chemically induced , Platelet Factor 4/immunology , Treatment Outcome , Venous Thrombosis/chemically induced , Fondaparinux , Anticoagulants/adverse effects , Necrosis
13.
Arch. endocrinol. metab. (Online) ; 59(4): 347-350, Aug. 2015. tab, ilus
Article in English | LILACS | ID: lil-757374

ABSTRACT

Advanced radioactive refractory and progressive or symptomatic differentiated thyroid carcinoma (DTC) is a rare condition. Sorafenib was recently approved for the treatment of these patients. We present the case of a 67 year old woman diagnosed with DTC who underwent a total thyroidectomy with central, lateral-compartment neck dissection and shaving of the trachea and esophagus due to tumor infiltration. A local recurrence was detected 14 months later requiring, additionally, two tracheal rings resection. The patient received a cumulative 131I dose of 650 mCi and developed dysphagia and dyspnea 63 months after initial surgery. A 18FGD-PET/CT showed progression of the local mass associated to hypermetabolic pulmonary nodules. Sorafenib 800 mg/day was then prescribed. A dose reduction to 400 mg/day was necessary due to grade 3 thrombocytopenia that appeared four months after drug prescription. Platelet count went to normal after this dose reduction. Five months after initiation of sorafenib, a partial response of the local mass with significant intra-tumoral necrosis was observed. We conclude that sorafenib is a valid option for locally advanced DTC and that the platelet count should be evaluated regularly because it seems that thrombocytopenia might be more frequently observed in DTC than in other types of tumors.


Subject(s)
Humans , Female , Aged , Phenylurea Compounds/therapeutic use , Thrombocytopenia/chemically induced , Thyroid Neoplasms/therapy , Niacinamide/analogs & derivatives , Neoplasm Recurrence, Local/therapy , Antineoplastic Agents/therapeutic use , Phenylurea Compounds/administration & dosage , Thyroidectomy , Thyroid Neoplasms/complications , Niacinamide/administration & dosage , Niacinamide/therapeutic use , Positron Emission Tomography Computed Tomography , Sorafenib , Neoplasm Staging , Antineoplastic Agents/administration & dosage
14.
Gut and Liver ; : 214-223, 2015.
Article in English | WPRIM | ID: wpr-136381

ABSTRACT

BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect against anemia during the early stages of HCV combination treatments but have also been associated with larger decreases in platelet counts. We aimed to identify the association between specific ITPA gene polymorphisms and hematological abnormalities in patients undergoing HCV combination therapy. METHODS: In this retrospective study, 175 patients treated with HCV combination therapy were enrolled at St. Martin De Porres Hospital in Taiwan between 2006 and 2012. Two single nucleotide polymorphisms (SNP) within or adjacent to the ITPA gene (rs1127354, rs6051702) were genotyped. We investigated the effect of ITPA gene variants on hematological abnormalities during the therapy. RESULTS: The ITPA rs1127354 minor variants were significantly associated with protection against anemia at week 4 (p=1.86 x 10(-6)) and with more severe decreases in platelet counts during HCV combination therapy. SNP rs6051702 was not associated with the hemoglobin decline to >3 g/dL at week 4 in our study (p=0.055). CONCLUSIONS: The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.


Subject(s)
Adult , Aged , Anemia/chemically induced , Antiviral Agents/adverse effects , Cross-Sectional Studies , Drug Therapy, Combination/adverse effects , Female , Hematologic Diseases/chemically induced , Hepacivirus , Hepatitis C/drug therapy , Humans , Interferon-alpha/adverse effects , Male , Middle Aged , Polymorphism, Single Nucleotide , Pyrophosphatases/genetics , Retrospective Studies , Ribavirin/adverse effects , Taiwan , Thrombocytopenia/chemically induced
15.
Gut and Liver ; : 214-223, 2015.
Article in English | WPRIM | ID: wpr-136380

ABSTRACT

BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect against anemia during the early stages of HCV combination treatments but have also been associated with larger decreases in platelet counts. We aimed to identify the association between specific ITPA gene polymorphisms and hematological abnormalities in patients undergoing HCV combination therapy. METHODS: In this retrospective study, 175 patients treated with HCV combination therapy were enrolled at St. Martin De Porres Hospital in Taiwan between 2006 and 2012. Two single nucleotide polymorphisms (SNP) within or adjacent to the ITPA gene (rs1127354, rs6051702) were genotyped. We investigated the effect of ITPA gene variants on hematological abnormalities during the therapy. RESULTS: The ITPA rs1127354 minor variants were significantly associated with protection against anemia at week 4 (p=1.86 x 10(-6)) and with more severe decreases in platelet counts during HCV combination therapy. SNP rs6051702 was not associated with the hemoglobin decline to >3 g/dL at week 4 in our study (p=0.055). CONCLUSIONS: The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.


Subject(s)
Adult , Aged , Anemia/chemically induced , Antiviral Agents/adverse effects , Cross-Sectional Studies , Drug Therapy, Combination/adverse effects , Female , Hematologic Diseases/chemically induced , Hepacivirus , Hepatitis C/drug therapy , Humans , Interferon-alpha/adverse effects , Male , Middle Aged , Polymorphism, Single Nucleotide , Pyrophosphatases/genetics , Retrospective Studies , Ribavirin/adverse effects , Taiwan , Thrombocytopenia/chemically induced
17.
Rev. latinoam. enferm ; 22(6): 911-917, 16/12/2014. tab
Article in English | LILACS, BDENF | ID: lil-732936

ABSTRACT

OBJECTIVE: to assess the quality of life of chronic kidney patients undergoing hemodialysis, using the WHOQOL-bref and WHOQOL-SRPB. METHOD: a descriptive and cross-sectional study was undertaken at a kidney replacement therapy service in the interior of the state of SP. The 110subjects who complied with the inclusion criteria answered the Subject Characterization Instrument, the WHOQOL-bref and WHOQOL-SRPB. RESULTS: most of the respondents were male (67.27%), with a mean age of 55.65 years, Catholic (55.45%), with unfinished primary education (33.64%) and without formal occupation (79.08%). The WHOQOL-bref domains with the highest and lowest mean score were, respectively, "psychological" (µ=74.20) and "physical" (µ=61.14). The WHOQOL-SRPB domains with the highest and lowest mean score were, respectively, "completeness and integration" (µ=4.00) and "faith" (µ=4.40). CONCLUSIONS: the respondents showed high quality of life scores, specifically in the dimensions related to spirituality, religion and personal beliefs. Losses were evidenced in the physical domain of quality of life, possibly due to the changes resulting from the chronic kidney disease and hemodialysis treatment. .


OBJETIVO: avaliar a qualidade de vida de pacientes renais crônicos em hemodiálise, por meio do WHOQOL-bref e WHOQOL-Spirituality, Religion and Personal Beliefs. MÉTODO: trata-se de um estudo descritivo, de corte transversal, realizado em uma unidade de terapia renal substitutiva do interior do Estado de São Paulo. Os 110 sujeitos que atenderam os critérios de inclusão responderam ao Instrumento de Caracterização dos Sujeitos, ao WHOQOL-bref e WHOQOL-Spirituality, Religion and Personal Beliefs. RESULTADOS: a maioria dos respondentes era do sexo masculino (67,27%), com idade média de 55,65 anos, católica (55,45%), com ensino fundamental incompleto (33,64%) e sem ocupação formal (79,08%). Os domínios do WHOQOL-bref com maior e menor pontuação média foram, respectivamente, "psicológico" (µ=74,20) e "físico" (µ=61,14). Os domínios do WHOQOL-Spirituality, Religion and Personal Beliefs de menor e maior pontuação média foram, respectivamente, "totalidade e integração" (µ=4,00) e "fé" (µ=4,40). CONCLUSÕES: os respondentes apresentaram elevados escores de qualidade de vida, especificamente nas dimensões referentes à espiritualidade, religião e crenças pessoais. Evidenciaram-se prejuízos no domínio físico da qualidade de vida, possivelmente em decorrência das alterações resultantes da doença renal crônica e do tratamento hemodialítico. .


OBJETIVO: evaluar la calidad de vida de pacientes renales crónicos en hemodiálisis, por medio del WHOQOL-bref y WHOQOL-SRPB. MÉTODO: se trata de un estudio descriptivo, de corte transversal, realizado en una unidad de terapia renal substitutiva del interior del estado de SP. Los 110 sujetos que atendieron a los criterios de inclusión respondieron al Instrumento de Caracterización de los Sujetos, al WHOQOL-bref y WHOQOL-SRPB. RESULTADOS: la mayoría de los entrevistados era del sexo masculino (67,27%), con edad promedio de 55,65 años, católicos (55,45%), con enseñanza fundamental incompleta (33,64%) y sin ocupación formal (79,08%). Los dominios del WHOQOL-bref con mayor y menor puntuación promedio fueron, respectivamente: "psicológico" (µ=74,20) y "físico" (µ=61,14). Los dominios del WHOQOL-SRPB de menor y mayor puntuación promedio fueron, respectivamente: "totalidad e integración" (µ=4,00) y "fe" (µ=4,40). CONCLUSIONES: los entrevistados presentaron elevados puntajes de calidad de vida, específicamente en las dimensiones referentes a espiritualidad, religión y creencias personales. Se evidenciaron perjuicios en el dominio físico de la calidad de vida, posiblemente en consecuencia de las alteraciones resultantes de la enfermedad renal crónica y del tratamiento de hemodiálisis. .


Subject(s)
Humans , Antineoplastic Agents/adverse effects , Bone Marrow/drug effects , Floxuridine/adverse effects , Administration, Oral , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/metabolism , Central Nervous System/drug effects , Floxuridine/administration & dosage , Floxuridine/metabolism , Heart/drug effects , Infusions, Intravenous , Leukopenia/chemically induced , Thrombocytopenia/chemically induced
18.
Indian J Dermatol Venereol Leprol ; 2013 July; 79 Suppl(): S35-46
Article in English | IMSEAR | ID: sea-147530

ABSTRACT

As elevated levels of tumor necrosis factor-alpha (TNF-α) are associated with disease severity in psoriasis and psoriatic arthritis, TNF-α antagonists are being used to treat moderate to severe disease in patients who have contraindications, fail to respond or develop side effects to conventional systemic therapies. It is of utmost importance to be well versed with the possible adverse effects and contraindications of TNF-α antagonists so that they can be used effectively and safely. Many of their adverse effects have been well studied in patients of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) and may not be completely applicable in psoriasis. This is because patients with RA and IBD are on multiple immunosuppressants while those with psoriasis are mostly receiving single systemic therapy and often have comorbidities that distinguish them from those with RA or IBD. Also, some of the side effects are still controversial and debated. Long-term prospective randomized controlled studies are needed to better understand the associated risk in patients of psoriasis. Baseline screening and periodic monitoring during treatment can reduce and help in early identification and appropriate management of the adverse outcomes. This article reviews the side effects known to be associated with TNF-α antagonists, their pathomechanisms and management guidelines. Some of the common side effects include infusion and injection site reactions, infections particularly reactivation of tuberculosis, autoantibody formation and drug induced lupus erythematosus, liver function abnormalities, hematological, and solid organ malignancies.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Drug Hypersensitivity/etiology , Drug Hypersensitivity/therapy , Humans , Immunoglobulin G/adverse effects , Injections/adverse effects , Latent Tuberculosis/chemically induced , Latent Tuberculosis/drug therapy , Liver/drug effects , Liver/physiopathology , Neoplasms/chemically induced , Nervous System Diseases/chemically induced , Psoriasis/chemically induced , Receptors, Tumor Necrosis Factor , Thrombocytopenia/chemically induced , Thromboembolism/chemically induced , Tumor Necrosis Factor-alpha/antagonists & inhibitors
19.
Indian J Dermatol Venereol Leprol ; 2013 Jul; 79(Suppl_7):s35-s46
Article in English | IMSEAR | ID: sea-154745

ABSTRACT

As elevated levels of tumor necrosis factor-alpha (TNF-α) are associated with disease severity in psoriasis and psoriatic arthritis, TNF-α antagonists are being used to treat moderate to severe disease in patients who have contraindications, fail to respond or develop side effects to conventional systemic therapies. It is of utmost importance to be well versed with the possible adverse effects and contraindications of TNF-α antagonists so that they can be used effectively and safely. Many of their adverse effects have been well studied in patients of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) and may not be completely applicable in psoriasis. This is because patients with RA and IBD are on multiple immunosuppressants while those with psoriasis are mostly receiving single systemic therapy and often have comorbidities that distinguish them from those with RA or IBD. Also, some of the side effects are still controversial and debated. Long-term prospective randomized controlled studies are needed to better understand the associated risk in patients of psoriasis. Baseline screening and periodic monitoring during treatment can reduce and help in early identification and appropriate management of the adverse outcomes. This article reviews the side effects known to be associated with TNF-α antagonists, their pathomechanisms and management guidelines. Some of the common side effects include infusion and injection site reactions, infections particularly reactivation of tuberculosis, autoantibody formation and drug induced lupus erythematosus, liver function abnormalities, hematological, and solid organ malignancies.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Drug Hypersensitivity/etiology , Drug Hypersensitivity/therapy , Humans , Immunoglobulin G/adverse effects , Injections/adverse effects , Latent Tuberculosis/chemically induced , Latent Tuberculosis/drug therapy , Liver/drug effects , Liver/physiopathology , Neoplasms/chemically induced , Nervous System Diseases/chemically induced , Psoriasis/chemically induced , Receptors, Tumor Necrosis Factor , Thrombocytopenia/chemically induced , Thromboembolism/chemically induced , Tumor Necrosis Factor-alpha/antagonists & inhibitors
20.
Rev. Assoc. Med. Bras. (1992) ; 59(2): 161-166, mar.-abr. 2013.
Article in English | LILACS | ID: lil-673384

ABSTRACT

Heparin is a natural agent with antithrombotic action, commercially available for therapeutic use as unfractionated heparin and low molecular weight heparin. Heparin-induced thrombocytopenia (HIT) is a serious adverse reaction to heparin that promotes antibodymediated platelet activation. HIT is defined as a relative reduction in platelet count of 50% (even when the platelet count at its lowest level is above > 150 x 10(9)/L) occurring within five to 14 days after initiation of the therapy. Thrombocytopenia is the main feature that directs the clinical suspicion of the reaction and the increased risk of thromboembolic complications is the most important and paradoxical consequence. The diagnosis is a delicate issue, and requires a combination of clinical probability and laboratory tests for the detection of platelet activation induced by HIT antibodies. The absolute risk of HIT has been estimated between 1% and 5% under treatment with unfractionated heparin, and less than 1% with low molecular weight heparin. However, high-quality evidence about the risk of HIT from randomized clinical trials is scarce. In addition, information on the frequency of HIT in developing countries is not widely available. This review aims to provide a better understanding of the key features of this reaction and updated information on its frequency to health professionals and other interested parties. Knowledge, familiarity, and access to therapeutic options for the treatment of this adverse reaction are mandatory to minimize the associated risks, improving patient safety.


A heparina é um agente natural com ação antitrombótica, sendo disponibilizadas para uso terapêutico a heparina não fracionadaeaheparina de baixo peso molecular. A trombocitopenia induzida por heparina (TIH) é uma reação adversa grave às heparinas mediada por anticorpos que promovem ativação de plaquetas. A TIH é definida como uma redução rela- tiva na contagem de plaquetas de 50% (mesmo se a contagem de plaquetas no seu nível mais baixo estiver acima 150 x 10(9)/L) que pode ocorrer no período de cinco a 14 dias após o início da terapia com o medicamento. A trombocitopenia é a principal característica que direciona a suspeita clínica da reação, sendo o aumento do risco de complicações tromboembólicas a consequência mais importante e paradoxal. O diagnóstico é uma questão delicada e requer a combinação da probabilidade clínica com testes laboratoriais para detectar a ativação plaquetária induzida pelos anticorpos da TIH. O risco absoluto de TIH tem sido estimado entre 1 e 5% no tratamento com heparina não fracionada e inferior a 1% no uso de heparina de baixo peso molecular. No entanto, evidências de alta qualidade provenientes de ensaios clínicos randomizados sobre a frequência dessa reação são escassas. Além disso, informações sobre a frequência de TIH em países em desenvolvimento não são amplamente disponíveis. Esta revisão teve como objetivo fornecer aos profissionais de saúde e demais interessados um melhor conhecimento sobre a TIH e as principais características dessa reação, bem como apresentar dados atualizados sobre a frequência da mesma. Conhecimento, familiaridade e acesso a opções terapêuticas para o tratamento dessa reação adversa são necessários para minimizar os riscos associados, melhorando a segurança do paciente.


Subject(s)
Humans , Anticoagulants/adverse effects , Heparin/adverse effects , Thrombocytopenia/chemically induced , Anticoagulants/immunology , Heparin/immunology , Risk Assessment , Thrombocytopenia/diagnosis , Thrombocytopenia/immunology , Thrombocytopenia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL